| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 53 | 2020 | 778 | 5.280 |
Why?
|
| Gonadotropin-Releasing Hormone | 5 | 2019 | 32 | 1.630 |
Why?
|
| Antineoplastic Agents, Hormonal | 9 | 2019 | 99 | 1.520 |
Why?
|
| Prostate-Specific Antigen | 14 | 2019 | 138 | 1.400 |
Why?
|
| Androgen Antagonists | 7 | 2020 | 45 | 1.380 |
Why?
|
| Prostatectomy | 10 | 2018 | 87 | 1.260 |
Why?
|
| Urinary Bladder Neoplasms | 14 | 2014 | 138 | 1.230 |
Why?
|
| Neoplasm Recurrence, Local | 10 | 2017 | 446 | 1.070 |
Why?
|
| Antibodies, Monoclonal | 4 | 2013 | 511 | 0.990 |
Why?
|
| Testosterone | 6 | 2020 | 96 | 0.960 |
Why?
|
| Salvage Therapy | 4 | 2010 | 82 | 0.950 |
Why?
|
| Indium Radioisotopes | 3 | 2013 | 19 | 0.910 |
Why?
|
| Prostate | 10 | 2013 | 116 | 0.890 |
Why?
|
| Kidney Neoplasms | 9 | 2010 | 206 | 0.810 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 2013 | 137 | 0.780 |
Why?
|
| Carcinoma, Renal Cell | 8 | 2010 | 110 | 0.680 |
Why?
|
| Cryosurgery | 2 | 2010 | 53 | 0.660 |
Why?
|
| Carcinoma, Transitional Cell | 7 | 2011 | 41 | 0.630 |
Why?
|
| Neoplasm Staging | 18 | 2019 | 800 | 0.610 |
Why?
|
| Male | 78 | 2020 | 37321 | 0.570 |
Why?
|
| Oligopeptides | 2 | 2019 | 152 | 0.550 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2014 | 468 | 0.530 |
Why?
|
| Humans | 96 | 2020 | 68618 | 0.490 |
Why?
|
| Leuprolide | 3 | 2020 | 6 | 0.470 |
Why?
|
| Goserelin | 3 | 2008 | 6 | 0.450 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 3 | 2020 | 33 | 0.450 |
Why?
|
| Pelvic Neoplasms | 1 | 2013 | 13 | 0.440 |
Why?
|
| Aged | 39 | 2020 | 14862 | 0.430 |
Why?
|
| Bone Neoplasms | 3 | 2017 | 100 | 0.370 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2013 | 239 | 0.370 |
Why?
|
| Penis | 2 | 2011 | 25 | 0.350 |
Why?
|
| Acid Ceramidase | 4 | 2013 | 85 | 0.350 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 940 | 0.340 |
Why?
|
| Biomarkers, Tumor | 2 | 2014 | 508 | 0.320 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2005 | 144 | 0.320 |
Why?
|
| Disease-Free Survival | 5 | 2016 | 349 | 0.310 |
Why?
|
| Antineoplastic Agents | 7 | 2017 | 1070 | 0.310 |
Why?
|
| Middle Aged | 39 | 2020 | 21147 | 0.310 |
Why?
|
| Follicle Stimulating Hormone | 2 | 2019 | 29 | 0.310 |
Why?
|
| Neoplasm Seeding | 1 | 2007 | 7 | 0.310 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2008 | 85 | 0.310 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2014 | 2324 | 0.300 |
Why?
|
| Nephrectomy | 6 | 2010 | 103 | 0.300 |
Why?
|
| Cisplatin | 4 | 1998 | 192 | 0.280 |
Why?
|
| Prostatitis | 2 | 2016 | 10 | 0.280 |
Why?
|
| Lithotripsy | 2 | 2020 | 18 | 0.270 |
Why?
|
| Treatment Outcome | 17 | 2020 | 7029 | 0.270 |
Why?
|
| Retrospective Studies | 15 | 2020 | 7277 | 0.260 |
Why?
|
| Laparoscopy | 1 | 2007 | 237 | 0.260 |
Why?
|
| Watchful Waiting | 3 | 2015 | 25 | 0.250 |
Why?
|
| Nafcillin | 1 | 2004 | 3 | 0.250 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2004 | 22 | 0.240 |
Why?
|
| Abscess | 1 | 2004 | 37 | 0.240 |
Why?
|
| Camptothecin | 3 | 2014 | 39 | 0.240 |
Why?
|
| Methicillin Resistance | 1 | 2004 | 45 | 0.240 |
Why?
|
| Vancomycin | 1 | 2004 | 60 | 0.240 |
Why?
|
| Community-Acquired Infections | 1 | 2004 | 46 | 0.240 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2004 | 88 | 0.240 |
Why?
|
| Uracil | 1 | 2004 | 18 | 0.230 |
Why?
|
| Drugs, Chinese Herbal | 1 | 2004 | 15 | 0.230 |
Why?
|
| Thrombosis | 1 | 2005 | 218 | 0.230 |
Why?
|
| Urology | 3 | 2015 | 31 | 0.230 |
Why?
|
| Algorithms | 2 | 2007 | 1196 | 0.230 |
Why?
|
| Staphylococcus aureus | 1 | 2004 | 175 | 0.220 |
Why?
|
| Staphylococcal Infections | 1 | 2004 | 156 | 0.220 |
Why?
|
| Aged, 80 and over | 14 | 2020 | 4848 | 0.220 |
Why?
|
| Lymphatic Metastasis | 5 | 2016 | 274 | 0.210 |
Why?
|
| Mice, Nude | 9 | 2013 | 294 | 0.200 |
Why?
|
| Survival Rate | 6 | 2017 | 1056 | 0.200 |
Why?
|
| Penile Neoplasms | 2 | 2011 | 12 | 0.190 |
Why?
|
| Ceramides | 7 | 2010 | 578 | 0.190 |
Why?
|
| Dipyridamole | 2 | 1991 | 26 | 0.190 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2013 | 35 | 0.190 |
Why?
|
| Health Services Accessibility | 3 | 2012 | 581 | 0.190 |
Why?
|
| Risk Factors | 6 | 2017 | 5731 | 0.180 |
Why?
|
| Calculi | 1 | 2020 | 7 | 0.180 |
Why?
|
| Galactosylgalactosylglucosylceramidase | 4 | 2008 | 39 | 0.180 |
Why?
|
| Gastroenterologists | 1 | 2020 | 11 | 0.180 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2004 | 435 | 0.180 |
Why?
|
| Referral and Consultation | 2 | 2015 | 383 | 0.180 |
Why?
|
| Prospective Studies | 9 | 2016 | 3705 | 0.180 |
Why?
|
| Ureteral Diseases | 1 | 2000 | 5 | 0.180 |
Why?
|
| Ureteral Neoplasms | 1 | 2000 | 8 | 0.180 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2020 | 45 | 0.170 |
Why?
|
| State Government | 1 | 2020 | 34 | 0.170 |
Why?
|
| Nutrition Policy | 1 | 2020 | 44 | 0.170 |
Why?
|
| Patient Preference | 2 | 2010 | 57 | 0.170 |
Why?
|
| Benzamides | 3 | 2017 | 156 | 0.170 |
Why?
|
| Phenylthiohydantoin | 2 | 2017 | 12 | 0.170 |
Why?
|
| Adult | 21 | 2020 | 21403 | 0.170 |
Why?
|
| Time Factors | 7 | 2020 | 4655 | 0.160 |
Why?
|
| Population Surveillance | 2 | 2018 | 285 | 0.160 |
Why?
|
| Disease Progression | 5 | 2020 | 1038 | 0.160 |
Why?
|
| Public Health | 1 | 2020 | 201 | 0.150 |
Why?
|
| Follow-Up Studies | 10 | 2018 | 3259 | 0.150 |
Why?
|
| Prognosis | 6 | 2018 | 2093 | 0.150 |
Why?
|
| Lymph Node Excision | 4 | 2011 | 91 | 0.150 |
Why?
|
| Receptors, LHRH | 1 | 2017 | 5 | 0.150 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2017 | 13 | 0.150 |
Why?
|
| Kidney Diseases | 1 | 2000 | 307 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2019 | 1745 | 0.140 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2010 | 332 | 0.140 |
Why?
|
| Adenocarcinoma | 3 | 2013 | 475 | 0.140 |
Why?
|
| Capsid Proteins | 2 | 2006 | 27 | 0.140 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2011 | 629 | 0.140 |
Why?
|
| Neoplasm Metastasis | 4 | 2020 | 306 | 0.140 |
Why?
|
| Genetic Therapy | 3 | 2008 | 291 | 0.130 |
Why?
|
| Medication Adherence | 1 | 2019 | 335 | 0.130 |
Why?
|
| Apoptosis | 3 | 2007 | 1641 | 0.130 |
Why?
|
| Propanolamines | 2 | 2013 | 70 | 0.130 |
Why?
|
| Fluoroquinolones | 1 | 2016 | 49 | 0.130 |
Why?
|
| Kidney | 3 | 2001 | 945 | 0.130 |
Why?
|
| Biopsy | 4 | 2018 | 540 | 0.130 |
Why?
|
| Methoxsalen | 1 | 1994 | 1 | 0.120 |
Why?
|
| Multimodal Imaging | 2 | 2014 | 62 | 0.120 |
Why?
|
| Atherosclerosis | 1 | 2017 | 204 | 0.120 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2014 | 3 | 0.120 |
Why?
|
| Cost of Illness | 2 | 2013 | 206 | 0.120 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2014 | 15 | 0.120 |
Why?
|
| Neoadjuvant Therapy | 2 | 2012 | 104 | 0.120 |
Why?
|
| Mice | 11 | 2013 | 8474 | 0.120 |
Why?
|
| Positron-Emission Tomography | 2 | 2014 | 160 | 0.120 |
Why?
|
| Spouses | 2 | 2013 | 51 | 0.120 |
Why?
|
| Drug Administration Schedule | 3 | 2019 | 567 | 0.120 |
Why?
|
| Ultraviolet Rays | 1 | 1994 | 130 | 0.120 |
Why?
|
| Head and Neck Neoplasms | 3 | 2007 | 561 | 0.120 |
Why?
|
| Patient Selection | 2 | 2015 | 592 | 0.120 |
Why?
|
| Sensitivity and Specificity | 4 | 2013 | 1753 | 0.110 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2014 | 28 | 0.110 |
Why?
|
| Lymph Nodes | 2 | 2013 | 258 | 0.110 |
Why?
|
| Animals | 16 | 2017 | 20881 | 0.110 |
Why?
|
| Radiation Tolerance | 1 | 2013 | 30 | 0.110 |
Why?
|
| Nitriles | 4 | 2017 | 68 | 0.110 |
Why?
|
| Nephrons | 2 | 2010 | 17 | 0.110 |
Why?
|
| Urothelium | 2 | 2011 | 22 | 0.110 |
Why?
|
| Combined Modality Therapy | 6 | 2010 | 951 | 0.110 |
Why?
|
| Sphingolipids | 4 | 2013 | 337 | 0.110 |
Why?
|
| Amides | 1 | 2013 | 86 | 0.110 |
Why?
|
| Urinary Reservoirs, Continent | 2 | 2004 | 5 | 0.110 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 2 | 2020 | 348 | 0.110 |
Why?
|
| Sexual Partners | 1 | 2013 | 106 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2015 | 504 | 0.110 |
Why?
|
| Hormone Antagonists | 1 | 2012 | 6 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2010 | 536 | 0.100 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2012 | 22 | 0.100 |
Why?
|
| Financing, Personal | 1 | 2012 | 17 | 0.100 |
Why?
|
| Biopsy, Needle | 2 | 2010 | 191 | 0.100 |
Why?
|
| Sexual Behavior | 1 | 2013 | 183 | 0.100 |
Why?
|
| Cell Line, Tumor | 7 | 2013 | 1851 | 0.100 |
Why?
|
| Liver Neoplasms | 1 | 2016 | 334 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2013 | 756 | 0.100 |
Why?
|
| Immunotherapy | 4 | 2017 | 215 | 0.100 |
Why?
|
| Up-Regulation | 3 | 2009 | 682 | 0.100 |
Why?
|
| Interpersonal Relations | 1 | 2013 | 209 | 0.100 |
Why?
|
| Electron Transport Chain Complex Proteins | 1 | 2011 | 7 | 0.100 |
Why?
|
| United States | 7 | 2020 | 7367 | 0.100 |
Why?
|
| Female | 23 | 2014 | 38074 | 0.100 |
Why?
|
| Urologic Neoplasms | 1 | 2011 | 14 | 0.100 |
Why?
|
| Cholecalciferol | 1 | 2012 | 143 | 0.090 |
Why?
|
| DNA, Mitochondrial | 1 | 2011 | 84 | 0.090 |
Why?
|
| Delayed Diagnosis | 1 | 2011 | 39 | 0.090 |
Why?
|
| Ureter | 2 | 2001 | 16 | 0.090 |
Why?
|
| Anilides | 2 | 2013 | 16 | 0.090 |
Why?
|
| Professional-Family Relations | 1 | 2011 | 45 | 0.090 |
Why?
|
| Testicular Neoplasms | 1 | 1990 | 27 | 0.090 |
Why?
|
| Adenoviridae | 3 | 2006 | 295 | 0.090 |
Why?
|
| Carcinoma | 1 | 2012 | 215 | 0.090 |
Why?
|
| Specialization | 1 | 2010 | 66 | 0.090 |
Why?
|
| Enzyme Inhibitors | 3 | 2008 | 659 | 0.090 |
Why?
|
| Orchiectomy | 2 | 2017 | 25 | 0.090 |
Why?
|
| Gallstones | 1 | 2010 | 58 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 3 | 2011 | 369 | 0.090 |
Why?
|
| Socioeconomic Factors | 2 | 2011 | 955 | 0.090 |
Why?
|
| Family | 1 | 2012 | 293 | 0.090 |
Why?
|
| Pancreatic Ducts | 1 | 2010 | 76 | 0.090 |
Why?
|
| Caregivers | 1 | 2013 | 365 | 0.090 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2005 | 129 | 0.090 |
Why?
|
| Patient Participation | 1 | 2011 | 146 | 0.080 |
Why?
|
| Dietary Supplements | 1 | 2012 | 332 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 1026 | 0.080 |
Why?
|
| Neoplasm, Residual | 1 | 2008 | 33 | 0.080 |
Why?
|
| Genes | 1 | 2008 | 86 | 0.080 |
Why?
|
| Perineum | 1 | 2008 | 11 | 0.080 |
Why?
|
| Autophagy | 1 | 2010 | 208 | 0.080 |
Why?
|
| Calcinosis | 1 | 2010 | 241 | 0.080 |
Why?
|
| Mucin-1 | 1 | 2008 | 35 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 4 | 2003 | 852 | 0.080 |
Why?
|
| Postoperative Complications | 4 | 2010 | 1615 | 0.080 |
Why?
|
| Pancreatitis, Chronic | 1 | 2010 | 168 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 710 | 0.080 |
Why?
|
| Lung Neoplasms | 2 | 2016 | 1173 | 0.080 |
Why?
|
| Indicators and Reagents | 1 | 2007 | 63 | 0.080 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2012 | 468 | 0.080 |
Why?
|
| Kallikreins | 2 | 2019 | 323 | 0.080 |
Why?
|
| beta-Defensins | 1 | 2007 | 8 | 0.080 |
Why?
|
| Genomics | 1 | 2008 | 168 | 0.070 |
Why?
|
| Antibodies | 1 | 2008 | 241 | 0.070 |
Why?
|
| Leiomyosarcoma | 1 | 2007 | 17 | 0.070 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2013 | 304 | 0.070 |
Why?
|
| Decision Making | 1 | 2011 | 410 | 0.070 |
Why?
|
| Vascular Neoplasms | 1 | 2007 | 15 | 0.070 |
Why?
|
| Complement System Proteins | 1 | 2008 | 135 | 0.070 |
Why?
|
| Vena Cava, Inferior | 1 | 2007 | 41 | 0.070 |
Why?
|
| Immunity, Innate | 1 | 2007 | 156 | 0.070 |
Why?
|
| Gene Expression | 4 | 2013 | 770 | 0.070 |
Why?
|
| Mitochondria | 1 | 2011 | 643 | 0.070 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2007 | 194 | 0.070 |
Why?
|
| Preventive Medicine | 1 | 2006 | 48 | 0.070 |
Why?
|
| Vascular Surgical Procedures | 1 | 2007 | 168 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2008 | 1664 | 0.060 |
Why?
|
| Community Networks | 1 | 2006 | 96 | 0.060 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2006 | 114 | 0.060 |
Why?
|
| Down-Regulation | 3 | 2014 | 447 | 0.060 |
Why?
|
| BCG Vaccine | 1 | 2005 | 12 | 0.060 |
Why?
|
| Cystectomy | 1 | 2005 | 13 | 0.060 |
Why?
|
| Orchitis | 1 | 2004 | 1 | 0.060 |
Why?
|
| Transurethral Resection of Prostate | 1 | 2004 | 1 | 0.060 |
Why?
|
| Suppuration | 1 | 2004 | 3 | 0.060 |
Why?
|
| Ciprofloxacin | 1 | 2004 | 30 | 0.060 |
Why?
|
| Urinary Bladder | 1 | 2005 | 108 | 0.060 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2004 | 30 | 0.060 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2004 | 47 | 0.060 |
Why?
|
| Doxycycline | 1 | 2004 | 49 | 0.060 |
Why?
|
| Clinical Protocols | 1 | 2005 | 172 | 0.060 |
Why?
|
| Boron Neutron Capture Therapy | 1 | 2004 | 3 | 0.060 |
Why?
|
| Disease Models, Animal | 1 | 1991 | 2550 | 0.060 |
Why?
|
| Urinary Diversion | 1 | 2004 | 16 | 0.060 |
Why?
|
| Boron Compounds | 1 | 2004 | 21 | 0.060 |
Why?
|
| Neoplasm Proteins | 1 | 2006 | 307 | 0.060 |
Why?
|
| Disease Susceptibility | 1 | 2004 | 179 | 0.060 |
Why?
|
| Organ Specificity | 1 | 2004 | 167 | 0.060 |
Why?
|
| Hepatitis C | 1 | 2004 | 114 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2004 | 649 | 0.050 |
Why?
|
| Brachytherapy | 2 | 2015 | 79 | 0.050 |
Why?
|
| Bacteremia | 1 | 2004 | 155 | 0.050 |
Why?
|
| Fluorouracil | 2 | 1994 | 130 | 0.050 |
Why?
|
| Young Adult | 3 | 2020 | 5717 | 0.050 |
Why?
|
| Recurrence | 1 | 2004 | 948 | 0.050 |
Why?
|
| Radioisotope Renography | 1 | 2001 | 2 | 0.050 |
Why?
|
| Ureteral Obstruction | 1 | 2001 | 25 | 0.050 |
Why?
|
| Embolization, Therapeutic | 1 | 2003 | 150 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 2 | 2003 | 532 | 0.050 |
Why?
|
| Survival Analysis | 3 | 2003 | 714 | 0.050 |
Why?
|
| Subrenal Capsule Assay | 2 | 1991 | 3 | 0.050 |
Why?
|
| Catheters, Indwelling | 1 | 2001 | 72 | 0.050 |
Why?
|
| Urologic Surgical Procedures | 1 | 2001 | 47 | 0.050 |
Why?
|
| Papilloma | 1 | 2000 | 8 | 0.050 |
Why?
|
| Intermediate Filament Proteins | 1 | 2000 | 12 | 0.050 |
Why?
|
| Wounds, Gunshot | 1 | 2001 | 48 | 0.050 |
Why?
|
| Neoplasm Transplantation | 2 | 1991 | 160 | 0.050 |
Why?
|
| Diuretics | 1 | 2001 | 97 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2013 | 737 | 0.050 |
Why?
|
| Carcinoma, Papillary | 1 | 2000 | 35 | 0.050 |
Why?
|
| Gels | 1 | 2020 | 55 | 0.050 |
Why?
|
| Urologists | 1 | 2020 | 7 | 0.050 |
Why?
|
| Microspheres | 1 | 2020 | 59 | 0.050 |
Why?
|
| Thrombocytosis | 1 | 2000 | 7 | 0.050 |
Why?
|
| Drug Synergism | 2 | 1991 | 260 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 772 | 0.050 |
Why?
|
| Tosyl Compounds | 2 | 2013 | 6 | 0.050 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 1998 | 111 | 0.040 |
Why?
|
| Geographic Mapping | 1 | 2020 | 19 | 0.040 |
Why?
|
| Data Collection | 2 | 2012 | 420 | 0.040 |
Why?
|
| Consumer Behavior | 1 | 2020 | 68 | 0.040 |
Why?
|
| Hyaluronan Receptors | 1 | 2000 | 142 | 0.040 |
Why?
|
| Sodium | 1 | 2020 | 161 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2019 | 38 | 0.040 |
Why?
|
| Drug Substitution | 1 | 2019 | 19 | 0.040 |
Why?
|
| Urinary Bladder Diseases | 1 | 1998 | 26 | 0.040 |
Why?
|
| Vasculitis | 1 | 1998 | 33 | 0.040 |
Why?
|
| Cell Survival | 2 | 2007 | 901 | 0.040 |
Why?
|
| Hamartoma | 1 | 1998 | 24 | 0.040 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 1997 | 10 | 0.040 |
Why?
|
| Androstenes | 1 | 2017 | 6 | 0.040 |
Why?
|
| Androgens | 1 | 2017 | 41 | 0.040 |
Why?
|
| Radioisotopes | 1 | 2017 | 40 | 0.040 |
Why?
|
| Radium | 1 | 2017 | 12 | 0.040 |
Why?
|
| Bone Resorption | 1 | 2017 | 64 | 0.040 |
Why?
|
| Fas Ligand Protein | 2 | 2008 | 64 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2018 | 2358 | 0.030 |
Why?
|
| Neoplasms | 1 | 2008 | 1667 | 0.030 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2016 | 6 | 0.030 |
Why?
|
| Genes, Reporter | 2 | 2006 | 191 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2018 | 2007 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2016 | 132 | 0.030 |
Why?
|
| Carcinoma, Verrucous | 1 | 1995 | 5 | 0.030 |
Why?
|
| von Hippel-Lindau Disease | 1 | 1995 | 7 | 0.030 |
Why?
|
| Insulin Resistance | 1 | 2017 | 241 | 0.030 |
Why?
|
| Trioxsalen | 1 | 1994 | 1 | 0.030 |
Why?
|
| Suramin | 1 | 1995 | 9 | 0.030 |
Why?
|
| Laryngeal Neoplasms | 1 | 1995 | 47 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 2014 | 120 | 0.030 |
Why?
|
| Nausea | 1 | 2014 | 47 | 0.030 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2013 | 5 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2013 | 41 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 2014 | 83 | 0.030 |
Why?
|
| Cognitive Dysfunction | 1 | 2017 | 176 | 0.030 |
Why?
|
| Taxoids | 1 | 2013 | 41 | 0.030 |
Why?
|
| Neutropenia | 1 | 2014 | 72 | 0.030 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2013 | 30 | 0.030 |
Why?
|
| Injections, Intraperitoneal | 1 | 2013 | 89 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2013 | 71 | 0.030 |
Why?
|
| Transcription Factor AP-1 | 1 | 2013 | 61 | 0.030 |
Why?
|
| Chemoradiotherapy | 1 | 2013 | 54 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 2013 | 119 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2014 | 411 | 0.030 |
Why?
|
| Disease Management | 1 | 2015 | 248 | 0.030 |
Why?
|
| Stomach Neoplasms | 1 | 1993 | 64 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 848 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2013 | 226 | 0.030 |
Why?
|
| Personal Satisfaction | 1 | 2013 | 123 | 0.030 |
Why?
|
| Incidence | 2 | 2010 | 1603 | 0.030 |
Why?
|
| Income | 1 | 2013 | 167 | 0.030 |
Why?
|
| International System of Units | 1 | 2012 | 6 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2015 | 287 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2015 | 402 | 0.030 |
Why?
|
| Finger Injuries | 1 | 1992 | 3 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2016 | 1738 | 0.030 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2012 | 76 | 0.030 |
Why?
|
| Seminal Vesicles | 1 | 2011 | 7 | 0.030 |
Why?
|
| Urologic Surgical Procedures, Male | 1 | 2011 | 20 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2013 | 319 | 0.020 |
Why?
|
| Occupational Diseases | 1 | 1992 | 68 | 0.020 |
Why?
|
| Genome, Mitochondrial | 1 | 2011 | 12 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 306 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 615 | 0.020 |
Why?
|
| General Surgery | 1 | 1992 | 95 | 0.020 |
Why?
|
| Family Relations | 1 | 2011 | 47 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2011 | 208 | 0.020 |
Why?
|
| Lymphocytes | 1 | 2011 | 228 | 0.020 |
Why?
|
| Cell Line | 2 | 1991 | 1752 | 0.020 |
Why?
|
| Protein Binding | 1 | 2013 | 1027 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 1990 | 122 | 0.020 |
Why?
|
| Drug Therapy | 1 | 2010 | 71 | 0.020 |
Why?
|
| Methotrexate | 1 | 1990 | 91 | 0.020 |
Why?
|
| Etoposide | 1 | 1990 | 64 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 454 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2010 | 119 | 0.020 |
Why?
|
| Base Sequence | 1 | 2011 | 1015 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2011 | 201 | 0.020 |
Why?
|
| Mass Screening | 1 | 1995 | 843 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2010 | 239 | 0.020 |
Why?
|
| Myristates | 1 | 2008 | 21 | 0.020 |
Why?
|
| CD55 Antigens | 1 | 2008 | 13 | 0.020 |
Why?
|
| Membrane Cofactor Protein | 1 | 2008 | 7 | 0.020 |
Why?
|
| CD59 Antigens | 1 | 2008 | 30 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2008 | 188 | 0.020 |
Why?
|
| Tumor Escape | 1 | 2008 | 37 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2008 | 140 | 0.020 |
Why?
|
| Chicken anemia virus | 1 | 2008 | 5 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2010 | 311 | 0.020 |
Why?
|
| Social Support | 1 | 2011 | 423 | 0.020 |
Why?
|
| PAX2 Transcription Factor | 1 | 2007 | 11 | 0.020 |
Why?
|
| Renal Veins | 1 | 2007 | 18 | 0.020 |
Why?
|
| Replantation | 1 | 2007 | 8 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2007 | 54 | 0.020 |
Why?
|
| Phlebography | 1 | 2007 | 31 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2007 | 86 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2007 | 86 | 0.020 |
Why?
|
| Anastomosis, Surgical | 1 | 2007 | 104 | 0.020 |
Why?
|
| Antigens | 1 | 1987 | 90 | 0.020 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2008 | 201 | 0.020 |
Why?
|
| Vascular Patency | 1 | 2007 | 122 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 507 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2007 | 90 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1990 | 626 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 2007 | 357 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2008 | 791 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2008 | 312 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 434 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2007 | 242 | 0.020 |
Why?
|
| Phosphoserine | 1 | 2006 | 14 | 0.020 |
Why?
|
| Sphingosine | 1 | 2008 | 315 | 0.020 |
Why?
|
| Pain | 1 | 2010 | 472 | 0.020 |
Why?
|
| Desipramine | 1 | 2006 | 47 | 0.020 |
Why?
|
| Cell Death | 1 | 2007 | 329 | 0.020 |
Why?
|
| Endosomes | 1 | 2006 | 45 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2006 | 40 | 0.020 |
Why?
|
| Models, Biological | 1 | 1990 | 981 | 0.020 |
Why?
|
| Mutation | 1 | 2011 | 1213 | 0.020 |
Why?
|
| Caspases | 1 | 2006 | 194 | 0.020 |
Why?
|
| Diagnosis, Differential | 2 | 2000 | 1140 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 1174 | 0.020 |
Why?
|
| Lysosomes | 1 | 2006 | 136 | 0.020 |
Why?
|
| Protein Transport | 1 | 2006 | 280 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 1851 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2013 | 2800 | 0.020 |
Why?
|
| Tumor Necrosis Factors | 1 | 2005 | 4 | 0.020 |
Why?
|
| Viral Vaccines | 1 | 2005 | 17 | 0.020 |
Why?
|
| Cytosine Deaminase | 1 | 2005 | 8 | 0.020 |
Why?
|
| Thymidine Kinase | 1 | 2005 | 18 | 0.020 |
Why?
|
| Proteins | 1 | 2008 | 474 | 0.020 |
Why?
|
| Genes, p53 | 1 | 2005 | 41 | 0.020 |
Why?
|
| Ceramidases | 1 | 2005 | 47 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2006 | 376 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 2010 | 498 | 0.020 |
Why?
|
| Amidohydrolases | 1 | 2005 | 60 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 2223 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2006 | 525 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2006 | 231 | 0.020 |
Why?
|
| Sphingomyelin Phosphodiesterase | 1 | 2006 | 183 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2011 | 805 | 0.020 |
Why?
|
| Cell Movement | 1 | 2007 | 630 | 0.010 |
Why?
|
| Ileum | 1 | 2004 | 28 | 0.010 |
Why?
|
| Stomach | 1 | 2004 | 80 | 0.010 |
Why?
|
| Vinblastine | 1 | 2003 | 40 | 0.010 |
Why?
|
| Probability | 1 | 2003 | 245 | 0.010 |
Why?
|
| Karyotyping | 1 | 2003 | 74 | 0.010 |
Why?
|
| Colon | 1 | 2004 | 168 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2007 | 1174 | 0.010 |
Why?
|
| Intraoperative Complications | 1 | 2003 | 129 | 0.010 |
Why?
|
| Diethylstilbestrol | 1 | 2002 | 45 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2005 | 370 | 0.010 |
Why?
|
| Technetium Tc 99m Mertiatide | 1 | 2001 | 2 | 0.010 |
Why?
|
| Hospitals, General | 1 | 2001 | 12 | 0.010 |
Why?
|
| Urography | 1 | 2001 | 21 | 0.010 |
Why?
|
| Hydronephrosis | 1 | 2001 | 12 | 0.010 |
Why?
|
| Urinalysis | 1 | 2001 | 27 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 2001 | 95 | 0.010 |
Why?
|
| Keratin-20 | 1 | 2000 | 3 | 0.010 |
Why?
|
| Georgia | 1 | 2001 | 161 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2001 | 114 | 0.010 |
Why?
|
| World Health Organization | 1 | 2000 | 53 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2006 | 1293 | 0.010 |
Why?
|
| International Cooperation | 1 | 2000 | 88 | 0.010 |
Why?
|
| Platelet Count | 1 | 2000 | 100 | 0.010 |
Why?
|
| Connective Tissue | 1 | 2000 | 61 | 0.010 |
Why?
|
| Mucous Membrane | 1 | 2000 | 66 | 0.010 |
Why?
|
| South Carolina | 1 | 2006 | 2752 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2002 | 438 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2002 | 931 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2000 | 403 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 1997 | 125 | 0.010 |
Why?
|
| Neck | 1 | 1997 | 62 | 0.010 |
Why?
|
| Adolescent | 2 | 2001 | 8912 | 0.010 |
Why?
|
| Random Allocation | 1 | 1997 | 442 | 0.010 |
Why?
|
| Laryngectomy | 1 | 1995 | 30 | 0.010 |
Why?
|
| Methylnitrosourea | 1 | 1995 | 9 | 0.010 |
Why?
|
| Administration, Intravesical | 1 | 1995 | 8 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 1995 | 104 | 0.010 |
Why?
|
| Neoplasms, Second Primary | 1 | 1995 | 62 | 0.010 |
Why?
|
| Physical Examination | 1 | 1995 | 152 | 0.010 |
Why?
|
| ROC Curve | 1 | 1995 | 392 | 0.010 |
Why?
|
| Reference Values | 1 | 1995 | 579 | 0.010 |
Why?
|
| Gastrectomy | 1 | 1993 | 24 | 0.010 |
Why?
|
| Ultrasonography | 1 | 1995 | 453 | 0.010 |
Why?
|
| Needles | 1 | 1992 | 34 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 1995 | 1465 | 0.010 |
Why?
|
| Thymidine | 1 | 1990 | 32 | 0.010 |
Why?
|
| Age Factors | 1 | 1995 | 1864 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1990 | 196 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1990 | 351 | 0.010 |
Why?
|
| Cell Separation | 1 | 1990 | 132 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1990 | 489 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 1990 | 567 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1990 | 742 | 0.000 |
Why?
|
| Rats | 1 | 1995 | 5300 | 0.000 |
Why?
|